Legend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says

MT Newswires Live

07/27

Legend Biotech's (LEGN) data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.

The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.

RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.

The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.

RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.

Shares of the company were down more than 14% in Monday trading.

Price: 18.97, Change: -3.26, Percent Change: -14.65

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2654104947"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654104947\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654104947?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 23:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654104947","market":"us","top_or_hot":-1,"title":"Legend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says","media":"MT Newswires Live","content":"<html><body><p> Legend Biotech's (LEGN) data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.</p><p>The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.</p><p>RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.</p><p>The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.</p><p>RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.</p><p>Shares of the company were down more than 14% in Monday trading.</p><p>Price: 18.97, Change: -3.26, Percent Change: -14.65</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-27 23:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Legend Biotech's (LEGN) data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.</p><p>The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.</p><p>RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.</p><p>The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.</p><p>RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.</p><p>Shares of the company were down more than 14% in Monday trading.</p><p>Price: 18.97, Change: -3.26, Percent Change: -14.65</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAR","symbol_name":"安飞士","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654104947","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654104947","pubTimestamp":1785166365,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Legend Biotech's  data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.Shares of the company were down more than 14% in Monday trading.Price: 18.97, Change: -3.26, Percent Change: -14.65","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAR":"安飞士","BK4139":"生物科技","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","XBI":"SPDR S&P Biotech ETF","LEGN":"传奇生物","BK4022":"陆运","MEMS":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4230":"旅客陆运","BK4505":"高瓴资本持仓","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4588":"碎股","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4207":"综合性银行","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","CANC":"TEMA ONCOLOGY ETF","BK4581":"高盛持仓","MEDI":"HARBOR HEALTH CARE ETF","BK4585":"ETF&股票定投概念","GSIB":"THEMES GLOBAL SYSTEMICALLY IMPORTANT BANKS ETF"},"translate_title":"加拿大皇家银行资本市场表示，传奇生物的体内 CAR-T 细胞治疗数据验证了该方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1.5,"MEDI":0.6,"CANC":0.6,"LEGN":1.5,"MEMS":0.6,"GSIB":0.6,"XBI":1.5},"content_text":"Legend Biotech's (LEGN) data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.Shares of the company were down more than 14% in Monday trading.Price: 18.97, Change: -3.26, Percent Change: -14.65","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}